CTRI/2018/03/012906
Recruiting
未知
A large multicenter,international cohort study eveluating major vascular events in patients undergoing cardiac surgery - VISION Cardiac Surgery
Population Health Research Institution0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Population Health Research Institution
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Age \> 18 years
- •2\.Patients who have undergone cardiac surgery.This includes coronary artery bypass grafting and all open heart procedures such as valvular repairs/Replacement
Exclusion Criteria
- •1\.Previously enrolled in the VISION Cardiac Surgery
- •2\.Patients who have undergone an isolated pericardial window,pericardiectomy,permanent pacemaker or defibrillator implantation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2009-013884-21-DEEnceladus Pharmaceuticals BV90
Active, not recruiting
Phase 1
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)EUCTR2009-013884-21-BEEnceladus Pharmaceuticals BV90
Active, not recruiting
Not Applicable
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2009-013884-21-PLEnceladus Pharmaceuticals BV90
Completed
Not Applicable
International prospective multicenter cohort study for validation of the Chronic Pancreatitis Prognostic Scoring System (COPPS)K86.1Other chronic pancreatitisDRKS00022794Klinikum der Universität München, Campus Großhadern543
Recruiting
Not Applicable
International multicenter observational study to determine the diagnostic sensitivity of plasma metanephrines and urinary catecholamines and metabolites compared to standard evaluation procedures in children with high risk neuroblastomaNL-OMON51513Centre Hospitalier Universitaire Vaudois-CHUV30